Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (211-220 of 290) with videos related to

Pageof 29
Sort By:
Cancer Science|October 9, 2021
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Dai Maruyama, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2026
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma ProgressionYoko Nakanishi, Masaki Ri, Shiori Mizutani, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
International Journal of Hematology|May 23, 2019
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myelomaReham Ashour, Masaki Ri, Sanaa Shaker Aly, et al.
Hematological Oncology|August 31, 2022
CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatmentYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Bone Marrow Transplantation|February 21, 2019
Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agentsShohei Mizuno, Koji Kawamura, Ichiro Hanamura, et al.
British Journal of Haematology|July 25, 2024
Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantationKimimori Kamijo, Yoshimitsu Shimomura, Sung-Won Kim, et al.
British Journal of Haematology|January 7, 2016
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaTakashi Watanabe, Kensei Tobinai, Morio Matsumoto, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Pageof 29

Showing results (211-220 of 290) with videos related to

Sort By:
Pageof 29
Cancer Science|October 9, 2021
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Dai Maruyama, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2026
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma ProgressionYoko Nakanishi, Masaki Ri, Shiori Mizutani, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
International Journal of Hematology|May 23, 2019
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myelomaReham Ashour, Masaki Ri, Sanaa Shaker Aly, et al.
Hematological Oncology|August 31, 2022
CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatmentYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Bone Marrow Transplantation|February 21, 2019
Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agentsShohei Mizuno, Koji Kawamura, Ichiro Hanamura, et al.
British Journal of Haematology|July 25, 2024
Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantationKimimori Kamijo, Yoshimitsu Shimomura, Sung-Won Kim, et al.
British Journal of Haematology|January 7, 2016
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaTakashi Watanabe, Kensei Tobinai, Morio Matsumoto, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Pageof 29